J&J finishes enrollment for Phase 3 COVID-19
vaccine trials
Johnson & Johnson has fully enrolled the late-stage trials for
its COVID-19 vaccine candidate with 45,000 participants. The company also disclosed
that the vaccine has the potential to be given in one injection and will not
require ultra-cold storage.
Full Story: WBTS-TV
(Boston) (12/20)
No comments:
Post a Comment